Evidence map›Paper›PMID 33163191›Full record

ArticleGastroenterology report2020

Current trends in access to treatment for hepatitis B in immigrants vs non-immigrants.

Mireia Miquel, Albert Pardo, Montse Forné, Gemma Martínez-Alpin, Adrià Rodríguez-Castellano, Meritxell Casas, Mercè Rosinach, Mercè Roget, Blai Dalmau, Rocío Temiño and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Gastroenterology report, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Mireia MiquelLiver Unit, Gastroenterology Department, Parc Taulí University Hospital, Institut d'Investigacio i Innovació Parc Taulí I3PT, Autonomous University of Barcelona, Sabadell, Spain.ORCID 0000-0003-4566-4962
Albert PardoGastroenterology Department, University Hospital Joan XXIII, Tarragona, Spain.
Montse FornéCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
Gemma Martínez-AlpinLiver Unit, Gastroenterology Department, Consorci Sanitari de Terrassa, Terrassa, Spain.
Adrià Rodríguez-CastellanoGastroenterology Department, University Hospital Joan XXIII, Tarragona, Spain.
Meritxell CasasLiver Unit, Gastroenterology Department, Parc Taulí University Hospital, Institut d'Investigacio i Innovació Parc Taulí I3PT, Autonomous University of Barcelona, Sabadell, Spain.
Mercè RosinachLiver Unit, Gastroenterology Department, University Hospital Mútua Terrassa, Barcelona, Spain.
Mercè RogetLiver Unit, Gastroenterology Department, Consorci Sanitari de Terrassa, Terrassa, Spain.
Blai DalmauLiver Unit, Gastroenterology Department, Parc Taulí University Hospital, Institut d'Investigacio i Innovació Parc Taulí I3PT, Autonomous University of Barcelona, Sabadell, Spain.
Rocío TemiñoLiver Unit, Gastroenterology Department, University Hospital Mútua Terrassa, Barcelona, Spain.
Joan Carlos QuerGastroenterology Department, University Hospital Joan XXIII, Tarragona, Spain.
Jordi Sanchez-DelgadoLiver Unit, Gastroenterology Department, Parc Taulí University Hospital, Institut d'Investigacio i Innovació Parc Taulí I3PT, Autonomous University of Barcelona, Sabadell, Spain.
Jordi OrtizLiver Unit, Gastroenterology Department, Consorci Sanitari de Terrassa, Terrassa, Spain.
Mercedes VergaraLiver Unit, Gastroenterology Department, Parc Taulí University Hospital, Institut d'Investigacio i Innovació Parc Taulí I3PT, Autonomous University of Barcelona, Sabadell, Spain.
Universitat Autònoma de Barcelona · ESConsorci Sanitari de Terrassa · ESHospital Universitari Joan XXIII de Tarragona · ESUniversity Hospital Mútua de Terrassa · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUniversal vaccination for hepatitis B virus (HBV) and migratory movements have changed the demographic characteristics of this disease in Spain and in Europe. Therefore, we evaluated the characteristics of the disease and the possible differences according to origin (immigrants vs non-immigrants) and access to treatment.

methodsThis is a multicenter cross-sectional study (June 2014 to May 2015) in which outpatients with a positive HBsAg were seen and followed in four Hepatology units. Demographic and clinical data and indication and access to treatment were collected in two different regions of Catalonia (Spain) where there are no barriers to treatment due to a comprehensive coverage under the National Health System.

resultsA total of 951 patients were evaluated (48.1% men). Of these, 46.6% were immigrants (58.7% of them were born in Africa) and were significantly younger compared to non-immigrants. The proportions of patients with alcohol consumption, being overweight, and other indicators of metabolic co-morbidities were significantly higher in non-immigrants. Among the 937 patients receiving HBeAg examination, 91.7% were HBeAg-negative. Chronic HBeAg-positive infection was significantly higher in immigrants (3.9% vs 0.6%,

conclusionsThe immigrant population with HBV is younger and has a lower prevalence of metabolic co-morbidities and a higher frequency of chronic HBeAg infection. Despite having access to care and an indication for treatment, some do not get adequately treated due to several factors including local adaptation that precludes access to treatment.

Indexed as

access to treatmenthepatitis Bimmigrationprevalence

Identifiers

PMID33163191
PMCPMC7603864
OpenAlexW3013433653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.